Unique ID issued by UMIN | UMIN000042887 |
---|---|
Receipt number | R000048952 |
Scientific Title | Severe anaphylaxis caused by intravenous anti-cancer drugs |
Date of disclosure of the study information | 2021/01/03 |
Last modified on | 2021/12/20 13:11:39 |
Severe anaphylaxis caused by intravenous anti-cancer drugs
Anti-cancer Drugs & Severe Anaphylaxis
Severe anaphylaxis caused by intravenous anti-cancer drugs
Anti-cancer Drugs & Severe Anaphylaxis
Japan |
Severe Anaphylaxis
Medicine in general |
Malignancy
NO
Aim of this study was to assess the incidence of severe anaphylaxis that was caused by anti-cancer medications and elucidate the high-risk situation.
Safety
incidence of severe anaphylaxis that was caused by anti-cancer medications
high-risk situation
Observational
Not applicable |
Not applicable |
Male and Female
All outpatients and in patients who underwent intravenous chemotherapy for any malignancy from January 1st, 2013 to October 30th, 2020
None
5000
1st name | Nobuyuki |
Middle name | |
Last name | Horita |
Yokohama City University
Chemotherapy Center
236-0004
3-9, Fukuura, Kanazawa, Yokohama, Japan
045-787-2800
horitano@yokohama-cu.ac.jp
1st name | Nobuyuki |
Middle name | |
Last name | Horita |
Yokohama City University
Ethical Guidelines for Medical and Health Research Involving Human Subjects
236-0004
3-9, Fukuura, Kanazawa, Yokohama, Japan
045-787-2800
horitano@yokohama-cu.ac.jp
Yokohama City University
None
Self funding
Yokohama City University
Yokohama City University
3-9 Fukuura, Kanazawa, Yokohama, Japan
045-370-7627
rinri@yokohama-cu.ac.jp
NO
2021 | Year | 01 | Month | 03 | Day |
Published
5584
Main results already published
2021 | Year | 01 | Month | 03 | Day |
2021 | Year | 01 | Month | 07 | Day |
2021 | Year | 02 | Month | 01 | Day |
2021 | Year | 12 | Month | 31 | Day |
Electronic medical chart of patients with cancers who underwent intravenous chemotherapy from January 2013 to October 2020 in a single university hospital will be retrospectively reviewed. Non-epithelial malignancies such as sarcoma and leukemia will be also allowed for our analysis. "Severe anaphylaxis" will be judged by Brown's criteria: typical presentation of anaphylaxis and one or more of hypoxia, hypotension, and neurologic compromise. Agresti-Coull method was used to estimate 95% confidence interval (CI) of incidence.
2021 | Year | 01 | Month | 03 | Day |
2021 | Year | 12 | Month | 20 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048952
Research Plan | |
---|---|
Registered date | File name |
Research case data specifications | |
---|---|
Registered date | File name |
Research case data | |
---|---|
Registered date | File name |